Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.
Non-Small Cell Lung Cancer|Pancreatic Cancer|Locally Advanced Solid Tumor|Metastatic Solid Tumor
DRUG: HMBD-001|DRUG: Docetaxel|DRUG: Nab-paclitaxel|DRUG: Gemcitabine
Incidence and Nature of Adverse Events (AEs), An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered to be related to the study treatment., From the time the ICF is signed until 30 days after last dose of study treatment|Arm A and B only: Incidence and nature of dose-limiting toxicities (DLTs) during the first cycle of treatment, DLTs will be assessed during the safety run-in phase and are defined as toxicities that meet pre-defined severity criteria and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first cycle (4 weeks for Arm A, 3 weeks for Arm B) of treatment, Arm A: During the first four weeks of study treatment Arm B: During the first three weeks of study treatment|Objective Response Rate (ORR) by RECIST V1.1, The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1, Up to 24 months
This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.